Abstract:Neuroblastoma (NB) is a predominantly pediatric cancer with greater than 90% of cases arising in children under the age of five. More than half of patients have metastases detected at diagnosis, and high-risk disease is associated with five-year survival rates of only 50–60 %. Standard therapy involves highly toxic chemotherapy, surgery, radiation, and immunotherapy, and less toxic, more specific targeted therapies are urgently needed. Genomic studies have identified common driver aberrations in high-risk NB, such as MYCN amplification. In addition, a proportion of high-risk patients harbor amplification or activating mutations in anaplastic lymphoma kinase ( ALK ), and co-occurrence of ALK mutations and MYCN amplification have been associated with aggressive disease. In this study, we analyzed the efficacy of a Phase Ia-cleared, orally bioavailable dual ALK and focal adhesion kinase (FAK) inhibitor, ESK440, in multiple preclinical NB models. ESK440 potently inhibited proliferation of NB cell lines, with increased sensitivity in cell lines harboring ALK aberrations. ALK, FAK, and downstream target activation were rapidly decreased upon ESK440 treatment, and this was associated with impaired cellular migration and invasion. Importantly, ESK440 treatment also decreased MYCN levels. NB cell line and patient-derived xenograft studies showed significant reduction in tumor growth in ESK440-treated mice with no signs of toxicity. In certain NB models, ESK440 showed comparable or enhanced efficacy to lorlatinib, another clinical ALK inhibitor, and a lorlatinib-resistant cell line (COG-N-561 LR) retained sensitivity to ESK440. These preclinical results indicate that ESK440 is a promising targeted agent for ALK-driven NB and support future clinical studies to evaluate its efficacy in NB patients.

Novel Src/Abl Tyrosine Kinase Inhibitor Bosutinib Suppresses Neuroblastoma Growth Via Inhibiting Src/Abl Signaling

Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo

BX-795 inhibits neuroblastoma growth and enhances sensitivity towards chemotherapy

Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis

The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma

A small-molecule inhibitor of UBE2N induces neuroblastoma cell death via activation of p53 and JNK pathways

Therapeutic benefit of the dual ALK/FAK inhibitor ESK440 in ALK-driven neuroblastoma

BI-D1870 Induces Mitotic Dysfunction and Apoptosis in Neuroblastoma by Regulating the PI3K-Akt-mTORC1 Signal Axis

Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma

BRD4 Inhibitor MZ1 Exerts Anti-Cancer Effects by Targeting MYCN and MAPK Signaling in Neuroblastoma.

Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK

Smoothened-Independent Activation of Hedgehog Signaling by Rearranged During Transfection Promotes Neuroblastoma Cell Proliferation and Tumor Growth

Novel Mdm2 Inhibitor Sar405838 (Mi-773) Induces P53-Mediated Apoptosis in Neuroblastoma

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

The Second-Generation ALK Inhibitor Alectinib Effectively Induces Apoptosis in Human Neuroblastoma Cells and Inhibits Tumor Growth in a TH-MYCN Transgenic Neuroblastoma Mouse Model.

TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI

BRD4 Inhibitor GNE987 Exerts Anti-Cancer Effects by Targeting Super-Enhancers in Neuroblastoma

GZD2202, a Novel TrkB Inhibitor, Suppresses BDNF-mediated Proliferation and Metastasis in Neuroblastoma Models

Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines

PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc

Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma